Physician profile
David Chudwin
NPI 1669472262
$3,297.44
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $369 · 2021: $569 · 2022: $989 · 2023: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $878.58 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $661.21 | 2019-2023 | Tezspire |
| Genzyme Corporation | $306.07 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $208.83 | 2019-2023 | Dupixent |
| Allergan, INC. | $125.00 | 2020 | |
| Aimmune Therapeutics, INC. | $118.55 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $110.03 | 2019-2021 | |
| Amgen INC. | $98.54 | 2021-2023 | Tezspire |
| Csl Behring | $84.19 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Genentech USA, INC. | $73.90 | 2020-2022 | |
| Shire North American Group INC | $73.59 | 2019 | |
| Octapharma USA, INC. | $67.78 | 2022-2023 | Cutaquig |
| Blueprint Medicines Corporation | $63.46 | 2022-2023 | Ayvakit |
| Pfizer INC. | $60.47 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $57.80 | 2020 | |
| Incyte Corporation | $55.12 | 2023 | Opzelura |
| Optinose US, INC. | $53.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $49.41 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.63 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.08 | 2022 | |
| Pharming Healthcare, INC. | $16.51 | 2022 | |
| Covis Pharma Gmbh | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chudwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.